Eosinophil Recruitment into Guinea Pig Lungs after PAF-acether and Allergen Administration: Modulation by Prostacyclin, Platelet Depletion, and Selective Antagonists
- 31 March 1988
- journal article
- research article
- Published by American Thoracic Society in American Review of Respiratory Disease
- Vol. 137 (4) , 948-954
- https://doi.org/10.1164/ajrccm/137.4.948
Abstract
Intravenous administration of PAF-acether to the guinea pig induces bronchoconstriction, hypotension, intravascular platelet aggregation, endothelial disruption, and platelet and neutrophil diapedesis. These effects are followed within 1 h by an eosinophilic infiltration into the bronchial walls, which was also noted after the administration of antigen to passively sensitized guinea pigs. Bronchoconstriction and eosinophil infiltration are 2 major features of asthma, and selective bronchial eosinophilia characterizes late asthmatic reactions. We compared the histologic effects of PAF-acether 6 and 24 h after its intravenous injection with those of experimental passive anaphylatic shock, which is used as a model for asthma. Six hours after PAF-acether or antigen (ovalbumin) administration, marked lung eosinophil infiltration, particularly in the bronchial walls, was noted, together with mucous plugs containing eosinophils in the bronchial lumen. Epithelial desquamation was followed after 24 h by mucous metaplasia of the bronchial epithelium. These effects were not observed when the inactive metabolite lyso-PAF was used. Our results agree fully with the suggestion that the eosinophil mediates the pathophysiology of bronchial asthma and releases materials toxic for the respiratory epithelium. Two PAF-acether antagonists (BN 52021 and WEB 2086) prevented the eosinophil infiltration triggered by PAF-acether and by antigen. When PAF-acether or ovalbumin were injected into guinea pigs after antiplatelet serum or prostacyclin, the eosinophil infiltration was significantly reduced, suggesting that platelets or another adenylate cyclase-sensitive cell are important for the subsequent PAF-acether-induced eosinophil infiltration. Our results support an essential role for PAF-acether in an experimental model of allergic asthma.This publication has 19 references indexed in Scilit:
- Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils.Journal of Clinical Investigation, 1986
- Generation and partial characterization of eosinophil chemotactic activity and neutrophil chemotactic activity during early and late-phase asthmatic response*Journal of Allergy and Clinical Immunology, 1986
- Interference of BN 52021 (ginkgolide B) with the bronchopulmonary effects of PAF-acether in the guinea-pigEuropean Journal of Pharmacology, 1986
- Failure of a combined anti-histamine and anti-leukotriene treatment to suppress passive anaphylaxis in the guinea-pigInternational Journal of Immunopharmacology, 1986
- 1-O-Alkyl-2-acyl-sn-glycero-3-phosphorylcholine is the precursor of platelet-activating factor in stimulated rabbit platelets. Evidence for an alkylacetyl-glycerophosphorylcholine cycleBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1985
- BN 52021 and related compounds: A new series of highly specific PAF-acether receptor antagonists isolated from Ginkgo biloba L.Blood & Vessel, 1985
- Paf-acether: a mediator of inflammation and asthmaTrends in Pharmacological Sciences, 1984
- Activation of basophil and mast cell histamine release by eosinophil granule major basic protein.The Journal of Experimental Medicine, 1983
- Preliminary studies of an acid-labile factor (ALF) in human sera that inactivates platelet-activating factor (PAF)Clinical Immunology and Immunopathology, 1980
- ROLE OF PLATELETS IN ASPIRIN-SENSITIVE BRONCHOCONSTRICTION IN THE GUINEA-PIG; INTERACTIONS WITH SALICYLIC ACIDBritish Journal of Pharmacology, 1978